Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
Recruiting
N/A
Interventional Study
Spinal Cord Injuries
Spinal Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 60 (estimated)
- Sponsor
- Loewenstein Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Currently, Enoxaparin is the usual prophylactic anticoagulant treatment at the acute and sub-acute phases of spinal cord injury (SCI). Patients at the sub-acute phase of SCI (rehabilitation) will be given either Enoxaparin 40 mg/day (control) or Apixaban 2.5-5 mg twice a day. Apixaban dose will be determined by the treating physician. Treatment will be continued for either 6 or 12 weeks following …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* spinal cord injury (traumatic of not traumatic), Hebrew speaker.
Exclusion Criteria:
* contra-indication for anticoagulant treatment
* concomitant treatment with any other anticoagulant
* anticoagulant treatment needed for indications other than VTE prevention following spin…
Contacts